期刊文献+

B型钠尿肽在慢性心力衰竭患者的检测及其心功能的价值 被引量:1

The Value of B Type Natriuretic Peptide in Patients With Chronic Heart Failure and Cardiac Function Detection
下载PDF
导出
摘要 目的探究B型钠尿肽(BNP)在慢性心力衰竭患者的检测及其心功能的价值。方法选择我院2015年1~12月收治的45例慢性心力衰竭患者,对其进行B型钠尿肽检测,分析BNP与心功能之间的关系。结果心功能Ⅰ、Ⅱ、Ⅲ、Ⅳ级患者BNP检测值分别为(151.93±28.83)pg/ml、(348.84±49.95)pg/ml、(602.84±89.85)pg/ml、(1103.43±25.84)pg/ml,由此可知NYHA心功能等级分级越高,其检测出的BNP数值越高,相邻心功能等级对比,P〈0.05;经治疗后,心功能Ⅰ、Ⅱ、Ⅲ、Ⅳ级患者BNP检测值分别为(95.87±16.73)pg/ml、(248.84±35.95)pg/ml、(418.97±61.87)pg/ml、(737.96±42.34)pg/ml,得知所有患者的BNP检测值与治疗前对比,P〈0.05。结论BNP检测数值可在一定程度上表达慢性心力衰竭的心功能等级,有一定的临床意义。 Objective Study of B type natriuretic peptide(BNP) in patients with chronic heart failure and cardiac function detection value. Methods 45 cases of chronic heart failure in our hospital from January to December 2015 were selected, and the relationship between BNP and cardiac function was detected by B. Results The BNP values of patients with type Ⅰ, Ⅱ, Ⅲ, Ⅳ cardiac function were(151.93±28.83)pg/ml,(348.84±49.95)pg/ml,(602.84±89.85)pg/ml,(1 103.43±25.84)pg/ml, we found that the higher the NYHA cardiac function grade, the higher the BNP value detected, the comparison of the adjacent cardiac function grades, P〈0.05. After treatment, the BNP values of patients with type Ⅰ,Ⅱ,Ⅲ,Ⅳcardiac function were(95.87±16.73)pg/ml,(248.84±35.95)pg/ml,(418.97±61.87)pg/ml,(737.96±42.34)pg/ml, we found that the BNP level in all patients was significantly lower than that before treatment, P〈0.05. Conclusion BNP can express the heart function of chronic heart failure to some extent, and it has a certain clinical significance.
作者 张小双
出处 《中国继续医学教育》 2016年第33期61-62,共2页 China Continuing Medical Education
关键词 心力衰竭 B型钠尿肽 心功能 Heart failure B-type natriuretic peptide Cardiac function
  • 相关文献

参考文献8

二级参考文献94

  • 1杨文,杨万勇.血浆BNP诊断心力衰竭的临床应用[J].中国实用医药,2007,2(36):57-58. 被引量:2
  • 2王兰兰,蔡蓓,刘兴斌,刘瑾,黄德嘉,唐江涛,李立新.N末端脑型钠尿肽定量检测在心力衰竭诊断中的价值[J].中华检验医学杂志,2006,29(1):35-38. 被引量:50
  • 3李德新,贾慧敏,王清涛.BNP的测定和临床应用的研究进展[J].现代生物医学进展,2006,6(10):139-142. 被引量:10
  • 4FDA,Guidance for industry,non-inferiority clinclal trials.www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM202140.pdf,2010.
  • 5Kragelund C,Gronning B Kober L,Hildebrandt p,et al.N-Terminal Pro-B-Type Natriurctic Peptide and Long-term Mortality in Stable Coronary Heart Diease.N Engl J Med,2005;352:666-675.
  • 6Januzzi JL,Kimmanade R,Lainchhury J,et al.NT-proBNP testing for diagnosis and short-term prognosisi in acute destabilized heart failure:an intcmatonal pooled analysisi of 1256 patients.European Heart Journa,2006; 27:330-337.
  • 7Dhaliwal AS,Deswal A,Pritchett A,et al.Reduction in BNP levels with treatment of decompensated heart failure and future clinical events.J Card Fail.2009 May; 15(4):293-299.
  • 8Muller T,Gegenhuber A,Dieplinger BA,et al.Longterm stability of endogenous B-type natriuretic peptide(BNP) and amino terminal proBNP(NT-proBNP)in frozen plasma samples.Clio Chera Lab Meal,2004; 42(8):942-944.
  • 9Peacock WF,Emerman CL,Silver MA.Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute dccompensated heart failure[J].Am J Emerg Med,2005;23:327-331.
  • 10Burger A J,Horten DP,LeJemtel T,et al.Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment patients with acutely decompensated congestive heart failure:The PRECEDENT Study[J].Am Heart J,2002;144:1102-1108.

共引文献129

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部